[Ruby_E_Template slug="buzzstream-header"]
Font ResizerAa
Brinks ReportBrinks Report
Search
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
Have an existing account? Sign In
Follow US
© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.
Business

Will Mounjaro Be the Game-Changer for Weight Loss and Diabetes in India?

Dolon Mondal
Last updated: March 20, 2025 3:36 pm
Dolon Mondal
Will Mounjaro Be the Game-Changer for Weight Loss and Diabetes in India?

Mounjaro: A New Hope for Weight Loss and Diabetes Management in India

In a significant move for healthcare in India, Eli Lilly has launched Mounjaro, a revolutionary injectable drug designed to tackle obesity and type 2 diabetes. This much-anticipated drug is priced at INR 3,500 for a 2.5 mg vial and INR 4,375 for a 5 mg vial. It promises to be a game-changer for millions struggling with weight-related health issues.

What is Mounjaro? Mounjaro, also known as Tirzepatide, is a once-a-week prescription medication. It helps regulate appetite, reduce food intake, and decrease body weight.

The drug works by activating both GIP and GLP-1 hormone receptors. These receptors play a crucial role in managing blood sugar levels and fat utilization. This dual action makes Mounjaro particularly effective for chronic weight management and improving glycemic control in adults with type 2 diabetes.

Why is This Launch Important?

India has the second-highest number of people with diabetes in the world, around 100 million. Obesity is a major risk factor for diabetes. It is connected to more than 200 health problems, including high blood pressure and heart disease. The arrival of Mounjaro gives new hope to people dealing with these issues

Also Read: New Hope for Cancer Patients! Zydus Lifesciences’ Apalutamide Tablets Approved by USFDA

Clinical Trials and Results

Mounjaro has been tested in two major global studies: SURMOUNT-1 and SURPASS. In the SURMOUNT-1 trial, people who took Mounjaro lost a lot of weight. At the highest dose, they lost an average of 21.8 kg. The SURPASS trials showed that Mounjaro also helps control blood sugar levels, which is very important for people with diabetes.

Commitment to India

Eli Lilly has set special prices for India to make sure more people can get this treatment. Winselow Tucker, who leads Lilly in India, said the company wants to work with the government and others to help people understand and manage obesity and diabetes better.

The launch of Mounjaro in India marks a significant step in addressing obesity and diabetes. With its proven results and affordable pricing, Mounjaro will help many people improve their health.

Also Read: Shilpa Medicare’s Stock Rises 10% on Cancer Therapy Deal with mAbTree

TAGGED:diabetes treatmentEli LillyIndia healthcareMounjaroobesity managementSURMOUNT trialsSURPASS trialsTirzepatideweight-loss drug
Previous Article Teen Screen Time Crisis: What Netflix’s ‘Adolescence’ Wants You to Know Teen Screen Time Crisis: What Netflix’s ‘Adolescence’ Wants You to Know
Next Article Unusual Bird Migration Patterns in the US Midwest: What’s Going On? Unusual Bird Migration Patterns in the US Midwest: What’s Going On?
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

You Might Also Like

BYD
AutomobileBusiness

BYD, World’s Top EV Maker, Slows Production and Delays Expansion Amid Sales Slump

By Dolon Mondal
Sensex Gains, Nifty Nears 22,500 on Crude Price Drop
Business

Sensex Gains, Nifty Nears 22,500 on Crude Price Drop

By Dolon Mondal
India's Business Growth Soars in May Despite Rising Inflation
Business

Strong Services Help India’s Business Grow in May Despite Rising Prices, Survey Shows

By Ankita Das
Tesla’s European Market Share Crashes 42%—Despite Surging EV Demand
Business

Tesla’s European Market Share Crashes 42%—Despite Surging EV Demand

By Dolon Mondal
[Ruby_E_Template slug="buzzstream-footer"]